The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Novo Nordisk's downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

According to the European Union, in 2024, EU exports of medicinal and pharmaceutical products increased by 13.5% compared ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...